Cargando…

Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as “toxic epidermal necrolysis-like”

Detalles Bibliográficos
Autores principales:	Eldani, Céline, Darrigade, Anne Sophie, Beylot-Barry, Marie, Jullie, Marie-Laure, Ducharme, Océane, Milpied, Brigitte, Pham-Ledard, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Libbey Eurotext 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195128/ https://www.ncbi.nlm.nih.gov/pubmed/36856394 http://dx.doi.org/10.1684/ejd.2022.4378

Ejemplares similares

Pembrolizumab-Induced Toxic Epidermal Necrolysis
por: Borg, Luca, et al.
Publicado: (2022)

Sweet‐like syndrome and multiple COVID arm syndrome following COVID‐19 vaccines: ‘specific’ patterns in a series of 192 patients
por: Darrigade, Anne‐Sophie, et al.
Publicado: (2022)

Long-lasting cutaneous tuberculosis owing to Mycobacterium bovis masquerading as sarcoidosis
por: Dequidt, Laure, et al.
Publicado: (2018)

Pembrolizumab-induced toxic epidermal necrolysis: case report
por: Chow, Kar Ven Cavan, et al.
Publicado: (2022)

Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis
por: Qiu, Connie, et al.
Publicado: (2020)

A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma
por: LUHERNE, Camille, et al.
Publicado: (2022)

Integrative diagnosis of primary cutaneous large B-cell lymphomas supports the relevance of cell of origin profiling
por: Gros, Audrey, et al.
Publicado: (2022)

Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis
por: Kian, Waleed, et al.
Publicado: (2021)

Efficacy and Safety of Tumour Necrosis Factor-α Antagonists for Folliculitis Decalvans: A Retrospective Case-series Pilot Study
por: DUPONT, Aurore, et al.
Publicado: (2023)

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
por: Ladouceur, Alexandra, et al.
Publicado: (2023)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
por: Park, Jonathan J., et al.
Publicado: (2023)

Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab
por: McCormick, Benjamin Joseph, et al.
Publicado: (2023)

Toxic Epidermal Necrolysis
por: Khalifian, Saami, et al.
Publicado: (2014)

Toxic epidermal necrolysis
por: Hoetzenecker, Wolfram, et al.
Publicado: (2016)

Ocular sequelae of epidermal necrolysis: French national audit of practices, literature review and proposed management
por: Thorel, Dhyna, et al.
Publicado: (2023)

Necrotic Lip Infection Complicated by Facial Cellulitis and Septic Thoracic Emboli in an 18-year-old Man: A Quiz
por: SARAUX, Olivier, et al.
Publicado: (2023)

Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!
por: Luherne, Camille, et al.
Publicado: (2019)

Response to low-dose intravenous immunoglobulin in a case of recalcitrant Darier disease
por: Legrand, Adeline, et al.
Publicado: (2020)

Réactions cutanées retardées après vaccination contre le SARS-CoV-2 : étude CoVacskin
por: Darrigade, A.S., et al.
Publicado: (2022)

Review of Toxic Epidermal Necrolysis
por: Harris, Victoria, et al.
Publicado: (2016)

Toxic Epidermal Necrolysis and Sepsis
por: Alves, Daniela Dias, et al.
Publicado: (2016)

Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity
por: Poglio, Sandrine, et al.
Publicado: (2020)

Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
por: Valentin, Julie, et al.
Publicado: (2021)

Successful Response of Pembrolizumab Rechallenge after Radiotherapy for a Patient with Bladder Cancer of Nonresponse of Pembrolizumab First Challenge
por: Ikeda, Taro, et al.
Publicado: (2021)

Carbamzepine-induced toxic epidermal necrolysis
por: Chowta, Nithyananda K., et al.
Publicado: (2011)

Ofloxacin-induced toxic epidermal necrolysis
por: Gupta, Gaurang
Publicado: (2014)

Toxic epidermal necrolysis induced by lansoprazole()
por: Fracaroli, Tainá Scalfoni, et al.
Publicado: (2013)

Rapidly Developing Toxic Epidermal Necrolysis
por: Poulsen, Viktoria Oline Barrios, et al.
Publicado: (2013)

Toxic epidermal necrolysis in hemodialysis patient
por: Mateti, Uday Venkat, et al.
Publicado: (2015)

Early Manifestations of Toxic Epidermal Necrolysis
por: Chapman, James, et al.
Publicado: (2017)

Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019)

Immune-Mediated Toxic Epidermal Necrolysis
por: Keerty, Dinesh, et al.
Publicado: (2020)

Allopurinol-Induced Toxic Epidermal Necrolysis
por: Buenrostro-Rubio, Ignacio, et al.
Publicado: (2019)

Toxic Epidermal Necrolysis Secondary to Metronidazole
por: Ali, Junaid, et al.
Publicado: (2021)

Pneumonia caused by toxic epidermal necrolysis
por: Doyle, Dominic, et al.
Publicado: (2022)

Multidisciplinary Treatment in Toxic Epidermal Necrolysis
por: Surowiecka, Agnieszka, et al.
Publicado: (2023)

Levofloxacin-Induced Toxic Epidermal Necrolysis
por: Khan, Andeebia A, et al.
Publicado: (2023)

Phenytoin-Induced Toxic Epidermal Necrolysis
por: Tunuguntla, Mounika Nagarani, et al.
Publicado: (2023)

Lamotrigine-associated toxic epidermal necrolysis
por: Farooq, Omair, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tuv559ip2p08dr641v6drnvg7a